This page shows the latest multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb (BMS) announced that analysis from two phase 3 trials of Zeposia (ozanimod) showed that early use of the treatment demonstrated cognitive benefits in people with relapsing multiple sclerosis
Biogen and Happify Health have revealed plans for a new collaboration to support people living with multiple sclerosis (MS), with the companies aiming to provide a digital solution for patient education
Biogen and MedRhythms have partnered in a new licence agreement to develop and commercialise an investigational prescription digital therapeutic, MR-004, that is focused on improving multiple sclerosis (MS) patients’ mobility
Roche has shared new Ocrevus (ocrelizumab) data that demonstrates its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS). ... Multiple sclerosis (MS) is a chronic
multiple sclerosis (RRMS) who have been treated with Kesimpta (ofatumumab). ... David Martin, chief executive officer, Multiple Sclerosis Trust: “Access to a range of different treatment options is important for people living with MS to manage their
This includes those patients diagnosed with blood cancers, those taking immunosuppressive drugs after an organ transplant, or for conditions including rheumatoid arthritis and multiple sclerosis.
More from news
Approximately 108 fully matching, plus 516 partially matching documents found.
If we take multiple sclerosis (MS) as a living example, we know that patient outcomes are better when patients have a key role to play in their ongoing treatment.
She highlighted a Lucid Group initiative that improved the delivery of multiple sclerosis services after collaborating with specialist nurses and taking the time to understand their issues.
as multiple sclerosis and migraine, to monitor their health and track the success of their medication.
and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s
of B and T cells outside the lymph nodes, to treat relapsing forms of multiple sclerosis. ... Despite the expectation that it will face intense competition in the crowded multiple sclerosis market, sales of $80m are forecast for this year, rising to
More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.
During her ten-year career at Roche, Horning helped to bring 15 new medicines to patients in a range of diseases, including cancer, multiple sclerosis, influenza and blindness. ... Sandra has significant industry expertise and vast experience in drug
vice president, multiple sclerosis/neurology and immunology.
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
Previously head of Sanofi Genzyme’s multiple sclerosis, oncology and immunology organisation, Sibold has experience in leading global therapy launches.
Most recently, Dr Antonijevic served as global head of early development in neurology, multiple sclerosis and ophthalmology at Sanofi Genzyme in the US.
More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.
UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis.
For example, new commonalities have been discovered between Type 1 diabetes, lupus, multiple sclerosis and rheumatoid arthritis, suggesting that drugs already in use to treat one autoimmune disease could be equally
Matt is 31 and was diagnosed with multiple sclerosis, a chronic immune mediated inflammatory condition, two years ago.
Our triMS.online virtual event series connects a diverse global audience of healthcare professionals working in multiple sclerosis.
UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis.
More from PMHub
Approximately 17 fully matching, plus 35 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...